Eflapegrastim is a Recombinant Protein owned by Hanmi Pharmaceuticals, and is involved in 8 clinical trials, of which 6 were completed, and 2 are ongoing.
Eflapegrastim (HM-10460A, LAPS-GCSF,SPI-2012) is a long-acting G-CSF analog. G-CSF is hematopoietic growth factor acting on the neutrophilic lineage. It binds to the specific G-CSF receptors (G-CSFR) on cell surface and stimulates the differentiation, proliferation, and activation of the neutrophilic granulocytes. G-CSF regulates the production of neutrophils within the bone marrow and affects neutrophil progenitor proliferation‚ differentiation and selected end-cell functional activation including enhanced phagocytic ability priming of the cellular metabolism associated with respiratory burst‚ antibody dependent killing.
The revenue for Eflapegrastim is expected to reach a total of $5.6bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Eflapegrastim NPV Report.
Eflapegrastim (Rolontis) is recombinant human granulocyte colony stimulating factor analog derived from E.coli. It is formulated as solution for subcutaneous route of administration. Rolontis is indicated for the treatment of severe neutropenia in patients receiving cytotoxic chemotherapy for solid cancer and malignant lymphoma.
Eflapegrastim (HM-10460A, LAPS-GCSF,SPI-2012) is under development for the treatment of chemotherapy induced neutropenia. The drug candidate is administered subcutaneously. It is a long-acting granulocyte colony-stimulating factor (G-CSF) analog. It is based on Lapscovery technology.
Spectrum Pharmaceuticals Overview
Spectrum Pharmaceuticals (Spectrum) is a biopharma company that acquires, develops, and commercializes novel drug candidates for treatment of cancer. The company’s pipeline products include ROLONTIS, for treatment of chemotherapy-induced neutropenia helps to reduce the frequency of multiplication of tumors. This product is in phase 3 trails.; Poziotinib, an irreversible tyrosine kinase inhibitor, for non-small cell lung cancer (NSCLC) tumors with various mutations. This product is in phase 2 trials and lead candidate for the organization. The company has R&D facilities in, Massachusetts and California, the US. The company operates in the US, Europe, Japan, and other countries. Spectrum is headquartered in Henderson, Nevada, the US.
The operating loss of the company was US$147.7 million in FY2021, compared to an operating loss of US$169.7 million in FY2020. The net loss of the company was US$158.6 million in FY2021, compared to a net loss of US$160.9 million in FY2020.
Quick View – Eflapegrastim
|Highest Development Stage|